Vericel (VCEL) EBT Margin (2011 - 2026)

Vericel (VCEL) posted EBT Margin of 2.28% for Q2 2026, up 122.78% sequentially from 9.99% in Q1 2026, and up 385.0% YoY from 0.47% in Q2 2025.

Analysis

Vericel (VCEL) EBT Margin (2011 - 2026) Analysis & Trends

Vericel has reported EBT Margin for 16 years, with the latest figure at 2.28% in Q2 2026.

Quarterly EBT Margin rose 385.0% year-over-year to 2.28% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 7.45% (up 492.0% YoY) and the FY2025 annual result came in at 6.29%, up 186.0% from the prior year.
EBT Margin rose to 2.28% in Q2 2026 per VCEL's latest filing, from 9.99% in the prior quarter.
Over five years, EBT Margin peaked at 26.47% in Q4 2024 and troughed at 358.02% in Q2 2023.
A 5-year average of 22.54% and a median of 8.55% in 2023 frame the typical range for EBT Margin.
The sharpest annual moves came in 2023 and 2024: EBT Margin plunged 33383 bps in 2023, then surged 34825 bps in 2024.
Over 5 years, EBT Margin stood at 12.57% in 2022, then jumped by 73 bps to 21.68% in 2023, then advanced by 22 bps to 26.47% in 2024, then decreased by 5 bps to 25.04% in 2025, then tumbled by 91 bps to 2.28% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 2.28%, 9.99%, and 25.04% for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	35.61%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	35.78%
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-528.97%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	18.33%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	13.77%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	12.09%
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-2.67%
10	Vericel	2.05 Bn	1.89 Bn	56.40 Mn	2.88%

Historic Data

Download Data